FindTrial
Sign In

CTCs in Lung Malignancies

Concordance study of Circulating Tumor Cells (CTCs) with Biopsy in Patients with newly diagnosed Lung Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/08/035450
Enrollment
138
Registered
2021-08-05
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

None listed

Sponsors

Datar Cancer Genetics Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Provision of signed dated informed consent form. Suspected to have malignancy or newly diagnosed for lung malignancy(therapy na�¯ve)

Exclusion criteria

Exclusion criteria: Failure to meet any or all of the above criteria. Positive for HIV, HBV, HCV, or tuberculosis. Received any type or anticancer treatment since diagnosis; includes systemic therapy, radiation or surgery. Received blood transfusion within last 30 days. Underwent PET-CT scan within last 5 days. Unable to undergo tissue biopsy as part of Standard diagnostic Workup.

Design outcomes

Primary

MeasureTime frame
1. To study the concordance of circulating tumor cells-based study with biopsy in patients with newly diagnosed lung epithelial malignancyTimepoint: Six Months—

Secondary

MeasureTime frame
To study the concordance of circulating tumor cells-based study with biopsy in patients with newly diagnosed lung epithelial malignancyTimepoint: Six Months—

Countries

India

Contacts

Public ContactDr Sudha Murthy

Datar Cancer Genetics Private Limited

dadasaheb.akolkar@datarpgx.com02536690804

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026